Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK to address surgery cancellations

This article was originally published in Clinica

Executive Summary

"There is no room for complacency." This is how the UK's Department of Health underlined its commitment to tackle surgery cancellations, in light of data released today. In England, during the period July-September (Q2 2006-07), 12,275 operations (0.8% of all elective surgery) were cancelled at the last minute for non-clinical reasons, a small improvement on the 13,058 of Q2 2005-06. Delays in re-arranging the operation, although significantly better than a year ago, remain a source of concern: 637 (5.2%) cases were not treated within 28 days; last year, the figure was 1,160 (8.9%). At the end of October 2006, the number of patients waiting in England over 13 weeks for an operation stood at 188,300, down 2.3% from September and 9.4% since October 2005. The NHS performs 662,000 more operations per year now than in 1997, the DoH notes.

You may also be interested in...



Finance Watch: VCs Are Sharing The Wealth With More Biopharmas

Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.

Study Says FDA Waited Too Long To Ban Pelvic Mesh For POP Repairs

Roughly 18.5% of patients who received reinterventions to fix mesh implants for pelvic organ prolapse (POP) repair experienced complications they will likely endure for the rest of their lives, and they also face a 2.5% higher rate of further surgeries than non-mesh patients, says a recent 54,194-woman study detailed in Obstetrics & Gynecology. The study authors lay out a case that the US FDA should have forced removal of mesh from the market sooner.

Execs On The Move: New R&D Chief Promotion At HAL Allergy; Two C-Level Appointments At Starkey

HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.

Topics

UsernamePublicRestriction

Register

MT053656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel